BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOLGet Free Report) in a note issued to investors on Thursday. The firm set a “sell” rating on the medical technology company’s stock.

Several other brokerages have also recently weighed in on BIOL. Ascendiant Capital Markets decreased their target price on BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Benchmark reaffirmed a “speculative buy” rating and set a $0.40 target price on shares of BIOLASE in a research note on Wednesday, October 2nd.

Check Out Our Latest Research Report on BIOL

BIOLASE Stock Performance

Shares of BIOL opened at $0.01 on Thursday. The firm has a market capitalization of $200,442.00, a price-to-earnings ratio of 0.00 and a beta of 0.67. BIOLASE has a one year low of $0.02 and a one year high of $1.94. The stock’s fifty day moving average is $0.02 and its 200-day moving average is $0.07.

Hedge Funds Weigh In On BIOLASE

An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC lifted its stake in BIOLASE, Inc. (NASDAQ:BIOLFree Report) by 1,068.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the quarter. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 as of its most recent filing with the Securities & Exchange Commission. 8.79% of the stock is currently owned by hedge funds and other institutional investors.

BIOLASE Company Profile

(Get Free Report)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.

Featured Articles

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.